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Introduction {#jah31496-sec-0004}
============

The main focus in the audit of pediatric cardiac surgery has been operative mortality, expressed as either 30‐day mortality[1](#jah31496-bib-0001){ref-type="ref"} or mortality at hospital discharge.[2](#jah31496-bib-0002){ref-type="ref"} These very early outcomes have improved significantly over time,[3](#jah31496-bib-0003){ref-type="ref"}, [4](#jah31496-bib-0004){ref-type="ref"} but while relevant to quality assurance, they cannot inform service improvements outside the hospital setting. There remains a significant risk of death or clinical deterioration following discharge after "successful" surgery. For instance, "interstage mortality" for infants with hypoplastic left heart syndrome (HLHS) was 12% within a recent multicenter trial.[5](#jah31496-bib-0005){ref-type="ref"} Single‐center reports indicate that home monitoring programs of enhanced postdischarge surveillance for HLHS reduce interstage mortality,[6](#jah31496-bib-0006){ref-type="ref"}, [7](#jah31496-bib-0007){ref-type="ref"}, [8](#jah31496-bib-0008){ref-type="ref"}, [9](#jah31496-bib-0009){ref-type="ref"} but this practice is not universally implemented[5](#jah31496-bib-0005){ref-type="ref"} and local protocols vary.[10](#jah31496-bib-0010){ref-type="ref"} Studies of postdischarge outcomes for congenital heart disease (CHD) other than HLHS are sparse,[11](#jah31496-bib-0011){ref-type="ref"} and a greater understanding of the risk of adverse outcomes after discharge among the broader patient population could usefully inform quality improvement efforts.

To this end, we undertook a national study of outcomes in the first year after discharge from hospital among infants undergoing intervention for CHD. Our first aim was to measure the rates of adverse outcomes at 1 year among this population and then identify patient‐level factors independently associated with these outcomes. Our second, complementary aim was to identify groups of patients who might benefit from different interventions because of the differing nature and scale of risk that they face. The adverse events of interest to us were deaths in the community and any unplanned readmissions to intensive care, regardless of outcome, in the first year after discharge, because these are potentially avoidable through improved care at or after discharge. Deaths in the first year postdischarge that occurred after a planned readmission to intensive care (typically for elective surgery as part of a prospectively planned, staged treatment pathway) were not a focus of this work because they are less likely to be remediable through improvements to care at or after discharge.

This national study was possible because of the United Kingdom\'s unique combination of mandatory national audit data sets for pediatric cardiac procedures (the National Congenital Heart Disease Audit \[NCHDA\][12](#jah31496-bib-0012){ref-type="ref"}) and pediatric intensive care unit (PICU) admissions (the Paediatric Intensive Care Audit Network \[PICANet\][13](#jah31496-bib-0013){ref-type="ref"}), which is augmented in England and Wales with independently ascertained life status tracking.

Methods {#jah31496-sec-0005}
=======

Ethics {#jah31496-sec-0006}
------

Approval was obtained from the London Central Research Ethics Committee (reference No. 12/LO/1398) and the National Health Service (NHS) Health Research Authority Confidentiality Advisory Group (reference No. ECC 6‐02 (FT5)/2012). Requirement for consent was waived.

Constructing the Data Set for Analyses {#jah31496-sec-0007}
--------------------------------------

### Data sources and patient population {#jah31496-sec-0008}

Two national audit data sets were used: NCHDA[12](#jah31496-bib-0012){ref-type="ref"} and PICANet.[13](#jah31496-bib-0013){ref-type="ref"} Data submission to each audit is mandatory, subject to external data validation,[14](#jah31496-bib-0014){ref-type="ref"}, [15](#jah31496-bib-0015){ref-type="ref"} and each audit has approval from the relevant regulatory authorities for use of patient identifiable data. The survival status of patients in NCHDA is independently verified for patients of English and Welsh centers by the UK Health and Social Care Information Centre by using their patients' unique identifier (NHS number).

All children who underwent their first interventional catheterization or cardiac surgery when younger than 1 year in the United Kingdom between January 1, 2005 and December 31, 2010 were identified in NCHDA (overseas patients without an NHS number were removed at this stage; patients treated in Northern Ireland and Scotland were later identified and excluded). Records within PICANet for these patients were then identified by a trusted third party using patient NHS number, and patients with record(s) in NHCDA but not in PICANet were removed and analyzed separately. Separate data extracts from each audit were provided to the study team, each with the same patient‐level identifier (pseudonymized NHS number). A single patient potentially had multiple procedure‐based records in the NCHDA extract and multiple admission‐based records in the PICANet extract. The study team constructed a single patient‐based analysis data set by linking events for the same patient using the patient‐level identifier, including cardiac‐related details and life status (NCHDA) and rich comorbidity and emergency PICU admission information (PICANet).

### Defining the index admission and index procedure {#jah31496-sec-0009}

The index admission for each child was defined as the continuous period as an inpatient within the pediatric cardiac center, including admission(s) to PICU, that included their first surgical procedure or their first definitive or initial staging interventional catheter procedure (see Data S1 for included catheterizations). This period defined the index length of stay (LOS). Within the NCHDA data set, each procedure is described based on up to 8 individual procedural International Paediatric and Congenital Cardiac Codes (IPCCCs).[16](#jah31496-bib-0016){ref-type="ref"} An algorithm developed by the NCHDA Steering Committee defines the specific procedure undertaken, based on the combinations of IPCCCs recorded. These defined "specific procedures" are listed in hierarchical order with the Norwood operation at the top and, for surgery, ligation of patent ductus arteriosus (PDA) at the bottom, with interventional catheter procedures appearing below surgeries in the hierarchy (see Data S1 for further details). For children who underwent \>1 procedure during their index admission, their index intervention was chosen to be the most complex according to this hierarchy.

### Exclusions {#jah31496-sec-0010}

Children who underwent only catheter procedure(s) listed as exclusions in Data S1, premature babies who had ligation of PDA only, and cardiac transplant patients were excluded from our analysis because they have their own discharge and follow‐up care pathways. Patients treated in Northern Ireland and Scotland were also removed because they do not have verified life status.

Candidate Patient Risk Factors {#jah31496-sec-0011}
------------------------------

Candidate nonmedical, preoperative and postoperative risk factors available in the patient‐based analysis data set that would be known at the point of discharge were identified: these are provided in Table [1](#jah31496-tbl-0001){ref-type="table-wrap"} (with further details regarding the definitions in Data S1 and Tables S1--S4). Each child\'s primary cardiac diagnosis was identified based on a hierarchical IPCCC coding map,[21](#jah31496-bib-0021){ref-type="ref"} which also identified records where there was a concurrent acquired cardiac diagnosis. Other clinical information, including the presence of comorbid conditions and postoperative complications, was based on a mapping of Read codes.[22](#jah31496-bib-0022){ref-type="ref"} Where both audits contained information on a particular risk factor, the most complete source was used. Clinical variables with multiple parameters were necessarily collapsed into broad groups before statistical analyses to reduce the degrees of freedom and, hence, the risk of overfitting.[23](#jah31496-bib-0023){ref-type="ref"} Table [2](#jah31496-tbl-0002){ref-type="table-wrap"} lists the diagnostic categories within each of the 4 primary cardiac groups used in the analyses.

###### 

Candidate Patient Risk Factors

  Candidate Factors                                                                Categories (or Examples)
  -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nonmedical factors                                                               
  Deprivation                                                                      English index of multiple deprivation[17](#jah31496-bib-0017){ref-type="ref"}
  Ethnicity                                                                        White, Mixed, Asian, Black, Chinese, "Other", not stated[18](#jah31496-bib-0018){ref-type="ref"}, [19](#jah31496-bib-0019){ref-type="ref"}
  Preprocedural risk factors                                                       
  Primary cardiac diagnosis group                                                  Hypoplastic left heart syndrome (HLHS), functionally univentricular heart (UVH) or pulmonary atresia with intact ventricular septum (PA+IVS), isolated ventricular septal defect (VSD) (a recognizable biventricular comparator group), "other" (all remaining primary diagnoses consisting of a broad range of biventricular conditions)
  Presence of an acquired cardiac diagnosis                                        For example, acquired atrioventricular block, cardiomyopathy, myocardial ischemia, endocardial fibroelastosis
  Index procedure group                                                            Initial staged, definitive repair, "ungrouped"
  Presence of a congenital anomaly                                                 For example, Downs syndrome, DiGeorge syndrome (22q11 deletion), urogenital/renal malformations, tracheal/tracheaoesophageal malformations, vision/hearing deficits and exomphalos/gastrointestinal malformations
  Presence of a neurodevelopmental condition                                       For example, epilepsy/seizures, developmental delay, sleep apnea, hydrocephalus, retinopathy of prematurity, stroke, hemiparesis/hemiplegia, anoxic encephalopathy, cerebral venous sinus thrombosis and cerebral palsy
  Prematurity                                                                      \<37 completed weeks' gestation
  Sex                                                                              Male, female
  Age at procedure                                                                 Age at index procedure
  Weight‐for‐age at procedure                                                      Calculated using World Health Organization reference standards[20](#jah31496-bib-0020){ref-type="ref"}
  Antenatal diagnosis                                                              Antenatal diagnosis of congenital heart defect
  Clinical deterioration prior to index intervention                               Emergency admission to intensive care involving retrieval by specialist team
  Postprocedural risk factors                                                      
  Index admission length of stay                                                   Continuous period as an inpatient within a specialist paediatric cardiac hospital or PICU that surrounds a child\'s first interventional cardiac procedure in infancy
  Receipt of renal support or extracorporeal life support during index admission   Including dialysis and hemofiltration
  Any adverse PICU events during index admission                                   For example, collapse or cardiac arrest, acquired injury or complications, a noncardiac operation
  Postprocedural morbidity during index admission                                  For example, postprocedural pneumothorax, mediastinitis, chylothorax, cardiac arrest after procedure
  Acquired comorbidities during index admission                                    For example, meconium aspiration syndrome, gastritis, liver failure, pneumonia, *Clostridium difficile* infection
  Any catheter or surgical procedures performed in addition to index procedure     Either before or after the index procedure and within the index admission

The candidate nonmedical, preoperative, and postoperative risk factors used in the analyses. These were all available in the patient‐based analysis data set and would be known at the point of discharge. See Data S1 and Tables S1--S4 for further details. PICU indicates pediatric intensive care unit.

###### 

Primary Cardiac Diagnosis Categories

  Cardiac Diagnosis Group                                                                                     Primary Cardiac Diagnosis Category
  ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hypoplastic left heart syndrome (HLHS)                                                                      HLHS
  Functionally univentricular heart (UVH) or pulmonary atresia (PA) with an intact ventricular septum (IVS)   UVH; PA+IVS
  Isolated ventricular septal defect (VSD)                                                                    Isolated VSD±interatrial communication (atrioventricular septal defect \[ASD\])±patent ductus arteriosus (PDA)
  Other                                                                                                       Common arterial trunk (truncus arteriosus); transposition of the great arteries (TGA)+VSD/double outlet right ventricle (DORV)‐TGA type; interrupted aortic arch; TGA (concordant atrioventricular and discordant ventriculoatrial connections) and intact ventricular septum; PA+VSD (including Fallot type); miscellaneous congenital primary diagnoses; ASD; Fallot/DORV‐Fallot type; aortic valve stenosis (isolated); tricuspid valve abnormality (including Ebstein); mitral valve abnormality (including supravalvar, subvalvar); totally anomalous pulmonary venous connection; aortic arch obstruction±VSD/ASD; pulmonary stenosis; subaortic stenosis (isolated); aortic regurgitation; interatrial communication (ASD); PDA; acquired noncongenital heart disease; arrhythmia; miscellaneous congenital terms; noncardiac or uncoded diagnosis

The 4 primary cardiac diagnosis groups used in the analyses, which aggregate a set of 26 primary cardiac diagnosis categories, thereby reducing the degrees of freedom and, hence, the risk of overfitting.[23](#jah31496-bib-0023){ref-type="ref"} The primary cardiac diagnosis categories themselves are based on a hierarchical IPCCC coding map[21](#jah31496-bib-0021){ref-type="ref"} (see Table S2).

### Missing data {#jah31496-sec-0012}

Where ethnic group was not available from PICANet, the NCHDA ethnic code was used to assign White, Asian, or Black ethnicity (which showed strong concordance across the 2 audits); sensitivity analyses were performed excluding records without PICANet‐derived ethnicity. Weight‐for‐age outside the range ±5 *z*‐scores was assumed to be erroneous and treated as missing.

Outcomes {#jah31496-sec-0013}
--------

For the majority of our analyses, an *adverse event* was defined as either death outside a PICU admission (ie, "in the community") or any emergency unplanned readmission to PICU, regardless of outcome, within 1 year after discharge from the index admission. We note the inclusion of nonfatal unplanned readmissions to PICU as these were considered "near misses" of relevance to informing service improvement. However, for the purposes of comparison with in‐hospital mortality rates and risk modeling, some analyses were restricted to fatal adverse events only (deaths outside a planned admission)---where this was the case, we state this clearly in the text. Note that this research was designed to inform improvements in services at discharge and in the community; therefore, we did not consider death within 1 year of discharge from the index admission that occurred during a planned readmission to intensive care (typically for elective surgery as part of a staged treatment pathway) as an adverse outcome. Such patients were important to include in the analysis, however, as the period before the second elective surgery in a staged treatment pathway is known to be particularly high risk for many patients.[5](#jah31496-bib-0005){ref-type="ref"} Age at death (if applicable) and life status were available in NCHDA, while emergency unplanned admissions to PICU were extracted from PICANet.

Statistical Methods {#jah31496-sec-0014}
-------------------

### Descriptive and univariate analyses {#jah31496-sec-0015}

Descriptive analyses were performed to characterize the data set, and univariate logistic regression analysis on complete case data was used to assess the relation of each candidate predictor with each outcome by using fractional polynomials to investigate departure from linearity. This informed which variables were considered in two additional, complementary strands of analysis: first, the development of a risk model for adverse event and, separately, for fatal adverse events only, to generate generalizable knowledge about the individual underlying risk factors; and second, the identification of patient groups differentiated by risk of adverse event to inform potential interventions that might benefit certain subgroups of the population.

### Developing risk models for adverse events and for fatal adverse events only {#jah31496-sec-0016}

The significant variables from the univariate analysis (*P*\<0.10) were investigated in a multivariable model for each outcome in turn. Initially, models were developed in which the continuous predictors were used and, where appropriate, suitable transformations were included. For the final model presentation, continuous predictors were categorized based on considerations of model interpretability as well as statistical performance.

Multiple imputation (assuming data were missing at random) was used to account for missing data when fitting the multivariable models. The imputation models included all risk factors considered in the univariate analysis (which we assume includes all predictors of missingness). We generated 20 data sets and ran a full logistic regression, using the whole data set and implementing a bootstrap (200 samples) for each imputed data set to correct for overfitting. Significant predictors were selected based on the inclusion frequency of each predictor over the imputed data sets (ie, the proportion of times that the factor appeared in the model[24](#jah31496-bib-0024){ref-type="ref"}; see Data S2 for further details). The final models were derived by fitting a logistic regression model for all significant predictors, and estimates were combined by using Rubin rules.[25](#jah31496-bib-0025){ref-type="ref"} Model performance was assessed in terms of discrimination and calibration. The c‐statistic (area under the receiver operator curve), corrected for overfitting by using the bootstrap, was used to summarize the discrimination of the models.[26](#jah31496-bib-0026){ref-type="ref"} The Hosmer--Lemeshow statistic was used to test calibration (goodness‐of‐fit), and the range of *P*‐values obtained over the 20 imputed data sets is presented.

Sensitivity of the results to adjustment for clustering at both the hospital level and the regional level (English Primary Care Trusts[27](#jah31496-bib-0027){ref-type="ref"}) was assessed for each model by using the complete case data. All analyses were performed in Stata 13,[28](#jah31496-bib-0028){ref-type="ref"} and a value of *P*\<0.05 was considered statistically significant unless otherwise stated.

### Identifying patient groups differentiated by risk of adverse event {#jah31496-sec-0017}

Classification and regression tree (CART) analysis was used to identify patient groups with different "profiles of risk" that could usefully inform the development of interventions targeted at different groups. For other examples of CART applications in health care, see references [29](#jah31496-bib-0029){ref-type="ref"}, [30](#jah31496-bib-0030){ref-type="ref"}, [31](#jah31496-bib-0031){ref-type="ref"}. The CART algorithm recursively partitioned the data into subsets that were as homogeneous as possible with respect to adverse event (ie, into subsets of increasing "purity").[32](#jah31496-bib-0032){ref-type="ref"} All variables significantly associated with adverse event in univariate analysis were included in the CART analysis, with continuous variables entered in their categorized form as per final risk model development. To prevent overfitting, the CART groups were developed in a random 60% of the data and, for reasons of statistical robustness and potential usability, we restricted the tree depth to 4 and required a minimum of 100 cases for branching to continue, with at least 50 cases in either branch. The resulting classification tree was applied to the remaining 40% of the data set and the occurrence of adverse events among patients at each node was compared with the corresponding group in the development set to assess model stability. For both data sets, the c‐statistic was calculated by assessing the final group characterizations obtained in the derivation data set as a predictor for adverse event. All analysis was performed in SPSS 22.[33](#jah31496-bib-0033){ref-type="ref"}

Results {#jah31496-sec-0018}
=======

Data Set {#jah31496-sec-0019}
--------

A total of 12 390 infants meeting the inclusion criteria and with a valid patient identifier were identified in NCHDA, of whom 9385 (76%) were linked to ≥1 record in PICANet. Of these, 115 children who had an excluded catheter procedure only, 765 premature babies who had ligation of PDA only, 24 cardiac transplant patients, and 505 patients from Scotland or Northern Ireland were removed. Of 3005 patients who had no linked PICANet record, 1225 would not have been included in our study as they were either from Scotland or Northern Ireland or were premature and undergoing a PDA procedure only. The remaining 1780 demonstrated a greater prevalence of minor forms of CHD than did patients in the study data set.

Of the 7976 patients included in our study, 333 (4.2%) died during their index admission and were excluded from our analyses, leaving a final analysis data set of 7643 infants who were discharged alive from their index admission. Of these, 246 (3.2%) died within 1 year after discharge from the index admission and not during a planned admission (fatal adverse events), and 514 (6.7%) either died or had an emergency unplanned readmission to PICU within 1 year (all adverse events). Finally, 115 (1.5%) children died during a planned admission to PICU within 1 year after discharge from the index admission (not considered an outcome in our analysis), giving an overall mortality within the year after discharge from index admission of 4.7%.

Descriptive and Univariate Analyses {#jah31496-sec-0020}
-----------------------------------

A summary of the descriptive and univariate logistic regression analyses is presented in the Data S2. There was no association identified with either outcome (fatal adverse events or all adverse events) and with either sex or the performance of additional cardiac catheterizations during the index procedure.

Developing Risk Models for Adverse Events and for Fatal Adverse Events Only {#jah31496-sec-0021}
---------------------------------------------------------------------------

In the multivariable analysis in which continuous variables were treated as such, the significant risk factors for both outcomes were age at procedure, weight‐for‐age *z*‐score, index procedure group, cardiac diagnosis group, noncardiac congenital anomaly, prematurity, ethnicity, and LOS in a specialist center. Preprocedural clinical deterioration was additionally significant to fatal adverse events only, while neurodevelopmental condition and acquired cardiac diagnoses were additionally significant to all adverse events. Details of these continuous regression models are presented in the Data S2. In the final model development, the continuous predictors were categorized as follows: age at index procedure (\>3 months old, 1--2 months old, 10--30 days, 0--10 days old); weight‐for‐age *z*‐score (\>−2 SDs, −2 to −4 SDs, \<−4 SDs); and length of stay (0--7 days, 7--30 days, \>1 month). Details of the final regression models for fatal adverse events and all adverse events are shown in Tables [3](#jah31496-tbl-0003){ref-type="table-wrap"} and [4](#jah31496-tbl-0004){ref-type="table-wrap"}. For all models, adjusting for clustering at either the hospital or regional level had no statistically significant impact on results when comparing models using Akaike criteria (we present the unadjusted results).

###### 

Final Logistic Regression Model for Fatal Adverse Events Only

  Patient Variable           Overall No. (%)   No. of (%) Fatal Adverse Events   Odds Ratio           SE     95% CI
  -------------------------- ----------------- --------------------------------- -------------------- ------ -------------
  Ethnicity                                                                                                  
  White                      5728 (75.0)       166 (2.9)                         Reference category          
  Mixed                      196 (2.6)         4 (2.0)                           0.68                 0.35   0.25--1.88
  Asian                      867 (11.3)        38 (4.4)                          1.38                 0.26   0.95--2.01
  Black                      345 (4.5)         12 (3.5)                          1.00                 0.31   0.54--1.85
  Chinese                    28 (0.4)          3 (3.6)                           1.46                 1.53   0.19--11.43
  Other                      133 (1.7)         12 (9.0)                          2.82                 0.94   1.46--5.44
  Not stated                 346 (4.5)         13 (3.8)                          1.53                 0.47   0.85--2.78
  Cardiac diagnosis group                                                                                    
  VSD                        1348 (17.6)       25 (1.9)                          Reference category          
  HLHS                       390 (5.1)         48 (12.3)                         3.07                 0.97   1.65--5.71
  UVH or PA+IVS              531 (7.0)         41 (7.7)                          2.31                 0.69   1.29--4.15
  Other                      5374 (70.3)       132 (2.5)                         1.12                 0.26   0.70--1.77
  Specific procedure group                                                                                   
  Corrective                 4973 (65.1)       86 (1.7)                          Reference category          
  Palliative                 1629 (21.3)       119 (7.3)                         2.14                 0.38   1.50--3.04
  Ungrouped                  1041 (13.6)       41 (3.9)                          1.77                 0.36   1.20--2.63
  Congenital anomaly                                                                                         
  No                         6035 (79.0)       156 (2.6)                         Reference category          
  Yes                        1608 (21.0)       90 (5.6)                          2.43                 0.37   1.81--3.27
  Prematurity                                                                                                
  No                         4714 (61.7)       161 (3.4)                         Reference category          
  Yes                        828 (10.8)        44 (5.3)                          1.64                 0.30   1.16--2.34
  Clinical deterioration                                                                                     
  No                         6174 (80.8)       161 (2.6)                         Reference category          
  Yes                        1469 (19.2)       85 (5.8)                          1.66                 0.24   1.25--2.22
  Age at index procedure                                                                                     
  \>3 mo                     3202 (41.9)       55 (1.7)                          Reference category          
  1--2 mo                    1427 (18.7)       45 (3.2)                          1.32                 0.28   0.87--2.01
  10--30 d                   1114 (14.6)       43 (3.9)                          1.89                 0.45   1.19--3.02
  0--10 d                    1900 (24.9)       103 (5.4)                         2.54                 0.60   1.61--4.03
  Weight‐for‐age *z*‐score                                                                                   
  \>−2 SDs                   4064 (53.2)       128 (3.1)                         Reference category          
  −2 to −4 SDs               2467 (32.3)       71 (2.9)                          1.59                 0.28   1.12--2.26
  \<−4 SDs                   584 (7.6)         19 (3.3)                          2.28                 0.61   1.34--3.87
  Index length of stay                                                                                       
  0--7 d                     2564 (33.5)       35 (1.4)                          Reference category          
  7--30 d                    4327 (56.6)       146 (3.4)                         1.56                 0.31   1.06--2.31
  \>1 mo                     752 (9.8)         65 (8.6)                          2.70                 0.63   1.71--4.26

Details of the final regression model for fatal adverse events (death within a year after discharge from the index admission and not during a planned admission). For each patient variable the number (percentage) of fatal adverse events, multivariable odds ratios, standard errors and 95% confidence intervals are presented and the reference category indicated. The overall number (percentage) of patients within each category for a given patient variable is also noted. HLHS indicates hypoplastic left heart syndrome; PA+IVS, pulmonary atresia with an intact ventricular septum; PICU, pediatric intensive care unit; UVH, functionally univentricular heart; VSD, ventricular septal defect.

###### 

Final Logistic Regression Model for Adverse Event

  Patient Variable             Overall Number (%)   Number (%) Adverse Events   OR                   SE     95% CI
  ---------------------------- -------------------- --------------------------- -------------------- ------ --------------
  Ethnicity                                                                                                 
  White                        5728 (75.0)          348 (6.1)                   Reference category          
  Mixed                        196 (2.6)            9 (4.6)                     0.63                 0.23   0.31--1.29
  Asian                        867 (11.3)           73 (8.4)                    1.21                 0.17   0.92--1.61
  Black                        345 (4.5)            34 (9.9)                    1.43                 0.29   0.96--2.12
  Chinese                      28 (0.4)             1 (3.6)                     0.65                 0.68   0.09--5.02
  Other                        133 (1.7)            19 (14.3)                   2.39                 0.65   1.40--4.08
  Not stated                   346 (4.5)            30 (8.7)                    1.76                 0.37   1.16--2.65
  Cardiac diagnosis group                                                                                   
  VSD                          1348 (17.6)          60 (4.5)                    Reference category          
  HLHS                         390 (5.1)            70 (18.0)                   2.46                 0.58   1.55--3.90
  UVH or PA+IVS                531 (7.0)            73 (13.8)                   2.15                 0.46   1.41--3.28
  Other                        5374 (70.3)          311 (5.8)                   1.20                 0.19   0.88--1.64
  Specific procedure group                                                                                  
  Corrective                   4973 (65.1)          219 (4.4)                   Reference category          
  Palliative                   1629 (21.3)          205 (12.6)                  1.65                 0.21   1.28--2.13
  Ungrouped                    1041 (13.6)          90 (8.7)                    1.61                 0.22   1.23--2.11
  Congenital anomaly                                                                                        
  No                           6035 (79.0)          305 (5.1)                   Reference category          
  Yes                          1608 (21.0)          209 (13.0)                  2.71                 0.29   2.19--3.35
  Neurodevelopment condition                                                                                
  No                           7336 (96.0)          439 (6.0)                   Reference category          
  Yes                          307 (4.0)            75 (24.4)                   2.81                 0.44   2.06--3.82
  Prematurity                                                                                               
  No                           4714 (61.7)          340 (7.2)                   Reference category          
  Yes                          828 (10.8)           93 (11.2)                   1.59                 0.21   1.22--2.06
  Acquired diagnosis                                                                                        
  No                           7164 (93.7)          457 (6.4)                   Reference category          
  Yes                          479 (6.3)            57 (11.9)                   1.85                 0.30   1.35--2.53
  Age at index procedure                                                                                    
  \>3 months old               3202 (41.9)          129 (4.0)                   Reference category          
  1--2 months old              1427 (18.7)          110 (7.7)                   1.59                 0.23   1.20--2.10
  10--30 days                  1114 (14.6)          90 (8.1)                    2.21                 0.37   1.59--3.06
  0--10 days old               1900 (24.9)          185 (9.7)                   2.93                 0.48   2.12--4.04
  Weight‐for‐age *z*‐score                                                                                  
  \>−2SD                       4064 (53.2)          243 (6.0)                   Reference category          
  −2 to −4 SD                  2467 (32.3)          168 (6.8)                   1.72                 0.22   1.34--2.21
  \<−4SD                       584 (7.6)            50 (8.6)                    2.60                 0.48   1.81 to 3.75
  Index length of stay                                                                                      
  0--7 days                    2564 (33.5)          84 (3.3)                    Reference category          
  7--30 days                   4327 (56.6)          302 (7.0)                   1.54                 0.21   1.19--2.00
  \>1 month                    752 (9.8)            128 (17.0)                  2.73                 0.44   1.99--3.75

Details of the final regression model for adverse event (either death or an emergency unplanned readmission to PICU within 1 year after discharge from the index admission). For each patient variable, the number (percentage) of adverse events, the multivariable odds ratios, SEs, and 95% CIs are presented and the reference category indicated. The overall number (percentage) of patients within each category for a given patient variable is also noted. HLHS indicates hypoplastic left heart syndrome; PA+IVS, pulmonary atresia with an intact ventricular septum; PICU, pediatric intensive care unit; UVH, functionally univentricular heart; VSD, ventricular septal defect.

The c‐statistic of the final (categorical) model for fatal adverse events was 0.78 (95% CI 0.75--0.82), indicating good discrimination (and only marginally less discriminative than the continuous model, c‐statistic 0.80). The final (categorical) model for all adverse events also showed good discrimination with a combined c‐statistic of 0.78 (0.75--0.80) compared with 0.78 for the continuous model. Calibration of the final categorical and continuous models for both outcomes was also good, with Hosmer--Lemeshow *P*‐values ranging from 0.10 to 0.75 across the models fitted on the 20 imputed data sets, indicating no statistically significant differences between observed and expected number of deaths when calculated in deciles of predicted risk for each of the imputed data sets.

Identifying Patient Groups Differentiated by Risk of Adverse Event {#jah31496-sec-0022}
------------------------------------------------------------------

The [Figure](#jah31496-fig-0001){ref-type="fig"} depicts the final tree generated with the CART analysis including the rate of adverse events and number of patients within each of the 6 discrete patient groups that were generated (further details presented in Table [5](#jah31496-tbl-0005){ref-type="table-wrap"}). Of the 18 candidate risk factors entered in the analysis, CART identified presence/absence of a neurodevelopmental condition (24% risk among 307 patients) as the best single discriminator between patients experiencing an adverse event or not. For those without a neurodevelopmental condition, the next best discriminator was whether the cardiac diagnosis was HLHS or (functionally univentricular heart/pulmonary atresia with an intact ventricular septum) (15.2% risk among 868 patients). For patients with neither of the first 2 risk factors, the next best discriminator was presence/absence of a congenital anomaly followed by the LOS (threshold 1 month) (8.6% risk in patients with a congenital anomaly and LOS of \<1 month, 24% in patients with congenital anomaly and LOS of \>1 month, and 9.3% in patients with no congenital anomaly and LOS of \>1 month). The remaining 4778 low‐risk patients with none of the above factors had an adverse event rate of 2.8%. The development and test sets had c‐statistics of 0.73 and 0.74, respectively.

![Classification and regression tree (CART) analysis. The stratification tree generated by the CART analysis and evaluated across the entire data set (see Table [5](#jah31496-tbl-0005){ref-type="table-wrap"} for a breakdown by development and test set). The number and rate of adverse events and the total number of patients are given for each node. HLHS indicates hypoplastic left heart syndrome; PA, pulmonary atresia; UVH, functionally univentricular heart; VSD, ventricular septal defect.](JAH3-5-e003369-g001){#jah31496-fig-0001}

###### 

Patient Groups Identified by Using CART Analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient Group   Group Characteristics             Possible Additional Risk Factors \[% Patient Group\]   No. of Patients   No. (%) of Adverse Events                                                                
  --------------- --------------------------------- ------------------------------------------------------ ----------------- --------------------------- ---------------- --------------------- --------------------- ---------------------
  1               Neurodevelopmental condition(s)   May also have:\                                        192               115                         307              53 (28%)              22 (19%)              75 (24%)
                                                    Congenital anomalies \[52%\]\                                                                                                                                     
                                                    HLHS, UVH/PA+IVS \[17%\]\                                                                                                                                         
                                                    LOS \>1 mo \[26%\]                                                                                                                                                

  2               No neurodev. conditions\          ---                                                    95                76                          171              20 (21%)              21 (28%)              41 (24%)
                  VSD/other\                                                                                                                                                                                          
                  Congenital anomalies\                                                                                                                                                                               
                  LOS \>1 mo                                                                                                                                                                                          

  3               No neurodev. conditions\          May also have:\                                        524\              344\                        868\             82 (16%)\             50 (15%)\             132 (15%)\
                  HLHS, UVH/PA+IVS                  congenital anomalies \[10%\]\                          HLHS=219\         HLHS=147\                   HLHS=366\        HLHS=37 (17%)\        HLHS=28 (19%)\        HLHS=65 (18%)\
                                                    LOS \>1 mo \[20%\]                                     UVH/PA+IVS=305    UVH/PA+IVS=197              UVH/PA+IVS=502   UVH/PA+IVS=45 (15%)   UVH/PA+IVS=22 (11%)   UVH/PA+IVS=67 (13%)

  4               No neurodev. conditions\          ---                                                    189               135                         324              20 (11%)              10 (7%)               30 (9%)
                  VSD/other\                                                                                                                                                                                          
                  No congenital anomalies\                                                                                                                                                                            
                  LOS \>1 mo                                                                                                                                                                                          

  5               No neurodev. conditions\          ---                                                    701               494                         1195             60 (9%)               43 (9%)               103 (9%)
                  VSD/other\                                                                                                                                                                                          
                  Congenital anomalies\                                                                                                                                                                               
                  LOS \<1 mo                                                                                                                                                                                          

  6               No neurodev. conditions\          ---                                                    2898              1880                        4778             88 (3%)               45 (2%)               133 (3%)
                  VSD/other\                                                                                                                                                                                          
                  No congenital anomalies\                                                                                                                                                                            
                  LOS \<1 mo                                                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We list the patient characteristics that define each group in terms of combinations of ≥1 of the following: absence/presence of neurodevelopmental (neurodev.) condition; absence/presence of congenital anomaly; low‐risk/high‐risk primary cardiac diagnosis; index length of stay \>1 or \<1 month. For each group, the number of patients and occurrence of adverse events in the development, test, and overall data set are provided. For patient group 3, figures are also provided for the 2 subcategories of primary cardiac diagnosis within the high‐risk group, namely hypoplastic left heart syndrome (HLHS) or functionally univentricular heart (UVH)/pulmonary atresia with intact ventricular septum (PA+IVS). CART indicates classification and regression tree; LOS, length of stay (index admission).

Discussion {#jah31496-sec-0023}
==========

Outcomes and Risk Factors {#jah31496-sec-0024}
-------------------------

The causes of attrition after hospital discharge are poorly understood compared with adverse events occurring in hospital, yet as in‐hospital care improves, these postdischarge deaths are becoming increasingly numerically significant. Of 7976 patients who had undergone an intervention for CHD in infancy, representing the caseload for England and Wales over a 6‐year period, 333 (4.2%) died during their index admission. Of those discharged alive, 246 (3.2%) died either outside the specialist hospital or after an emergency unplanned PICU readmission within 1 year (fatal adverse events). An additional 268 patients (3.6%) experienced unplanned urgent readmission to an intensive care unit but subsequently survived ("near misses"), giving a combined total of 514 (6.7%) adverse events. The data set was generated by linking 2 national audits, each documenting variables potentially associated with these postdischarge outcomes.

The following risk factors have previously been linked to adverse postdischarge outcomes: primary diagnosis (in particular, HLHS and other diagnoses requiring an initial palliative \[staged\] procedure[34](#jah31496-bib-0034){ref-type="ref"}, [35](#jah31496-bib-0035){ref-type="ref"}), noncardiac congenital anomalies[35](#jah31496-bib-0035){ref-type="ref"}, [36](#jah31496-bib-0036){ref-type="ref"}, prematurity[37](#jah31496-bib-0037){ref-type="ref"}, prolonged LOS[35](#jah31496-bib-0035){ref-type="ref"}, [36](#jah31496-bib-0036){ref-type="ref"} (indicating greater complexity and perhaps a surrogate for postprocedural complications[38](#jah31496-bib-0038){ref-type="ref"}), and ethnicity.[5](#jah31496-bib-0005){ref-type="ref"} The risk models in our study further identified lower weight‐for‐age at procedure (which may correlate with feeding difficulties in infancy, a known risk factor[39](#jah31496-bib-0039){ref-type="ref"}); additional acquired cardiac diagnoses and preoperative clinical deterioration (which may relate to studies indicating that severer forms of a given type of CHD are at risk of poor postdischarge outcome[5](#jah31496-bib-0005){ref-type="ref"}, [40](#jah31496-bib-0040){ref-type="ref"}); neurodevelopmental conditions (which may overlap with noncardiac anomalies); and younger age at surgery (which, in contrast to studies specifically relating to HLHS that indicate older age at surgery increases risk of interstage death,[41](#jah31496-bib-0041){ref-type="ref"}, [42](#jah31496-bib-0042){ref-type="ref"} may reflect a broader effect such as young neonates being at higher risk than older infants[34](#jah31496-bib-0034){ref-type="ref"}, [35](#jah31496-bib-0035){ref-type="ref"}).

Informing Quality Improvement {#jah31496-sec-0025}
-----------------------------

The data presented reflect outcomes within the context of recent historical provision of services for infants with major CHD and are potentially insightful for ongoing quality improvement initiatives. To this end, we used CART analysis to identify patient groups with different "profiles of risk" (ie, defined by both their *level* of risk and the nature of that risk) who might benefit from specific interventions. The 6 groups that were identified have levels of risk of adverse event between 3% and 24%, which is informative when considering which groups may be a priority for intervention, while the clinical characteristics underlying the risk of each patient group (defined in terms of neurodevelopmental conditions; cardiac diagnosis of HLHS, functionally univentricular heart, or pulmonary atresia with an intact ventricular septum; congenital anomalies; LOS \>1 month) can inform the type of intervention that might be most appropriate. For example, group 3 consists of those patients most widely recognized as vulnerable to late death and offered enhanced surveillance, namely patients with cardiac diagnoses of HLHS and other functionally univentricular heart conditions.[43](#jah31496-bib-0043){ref-type="ref"} For example, single‐center studies from the United States[7](#jah31496-bib-0007){ref-type="ref"}, [8](#jah31496-bib-0008){ref-type="ref"}, [43](#jah31496-bib-0043){ref-type="ref"} and Germany[9](#jah31496-bib-0009){ref-type="ref"} suggest that postdischarge packages for HLHS (home monitoring programs) reduce interstage mortality. However, groups 1 and 2 have a higher occurrence of adverse events, suggesting that it may also be important to mitigate risks arising from patient factors beyond cardiac diagnosis, in particular clinically significant neurodevelopmental conditions and congenital anomalies. The type of intervention appropriate for these typically complex and lifelong comorbidities may be very different from those currently aimed at mitigating the cardiac risk of functionally single‐ventricle and shunt‐dependent infants.

Strengths and Weaknesses {#jah31496-sec-0026}
------------------------

The national audit data underpinning this study offer a unique opportunity for a population‐based analysis of surgically treated infants with CHD. First, the data are of high quality as demonstrated by the results of a regular systematic independent validation process.[14](#jah31496-bib-0014){ref-type="ref"}, [15](#jah31496-bib-0015){ref-type="ref"} Second, the NHS number enabled late deaths outside treatment centers to be reliably ascertained by using life status tracking and enabled linkage between the two national audit data sets allowing their respective, and complementary, content to be used. Third, mandatory data submission means that all procedures for CHD are captured, the only exclusions being patients who traveled from overseas specifically for treatment (since these do not have an NHS number and would not form part of the follow‐up program for UK specialist centers); patients in NCHDA who could not be linked to any records in PICANet (which includes those cared for only in neonatal units, those with a missing NHS number in PICANet, and those who did not require intensive care admission in either a neonatal unit or PICU for the procedure), and who represent predominantly more minor forms of CHD including a large proportion of PDA‐only procedures and patients who are provided with follow‐up by other specialist teams (eg, transplant recipients, premature infants without CHD). Our findings may therefore be considered more generalizable than those based on single‐center studies or those from a more limited geographical area.

There are inherent limitations to using registry‐based data, including the inevitable reliance on the data items that were routinely captured, which did not incorporate every potential variable of interest. Examples of important data that we could not access include the presence of residual lesions such as atrioventricular valve regurgitation, which is a known risk factor for late death in HLHS,[5](#jah31496-bib-0005){ref-type="ref"} and information that is available later in the patient journey from outside the hospital such as weight gain, which is linked to late outcome.[39](#jah31496-bib-0039){ref-type="ref"} There was a need to form tractable groupings from the vast range of diagnostic and procedure codes available to reduce the degrees of freedom for statistical analyses. Given our primary objective to inform quality improvement initiatives directed against late deterioration and death, we prioritized identification of diagnoses known to be high risk, namely HLHS and functionally single‐ventricle patients.

Our study outcomes inevitably reflect recent health services specific to the United Kingdom as provided by the NHS and, further, relate to the English and Welsh populations in terms of ethnicity, which has known links to the distribution of congenital anomalies.[44](#jah31496-bib-0044){ref-type="ref"} Evidence from North American studies suggests higher mortality for infants with CHD from Black and Hispanic ethnic groups, this being linked to reduced access to care[45](#jah31496-bib-0045){ref-type="ref"}, [46](#jah31496-bib-0046){ref-type="ref"}, [47](#jah31496-bib-0047){ref-type="ref"}, [48](#jah31496-bib-0048){ref-type="ref"}; however, these ethnic groupings are not representative of our study population. The ethnicity category "Other" in our data set was found to be at greater multivariable risk of adverse late outcome, whereas the more prevalent Asian and Black ethnic groups were not. Information from the UK Census suggests this category is largely comprised of individuals born in the Far East (Philippines, Japan, Thailand, and Vietnam), Middle East, and North Africa.[49](#jah31496-bib-0049){ref-type="ref"} Infants with CHD from these ethnic groups could be in newly immigrant families where treatment may occur later in the disease process or access to care may be compromised for cultural or linguistic reasons. Interestingly, in our analysis, socioeconomic status (English index of multiple deprivation[17](#jah31496-bib-0017){ref-type="ref"}) was not associated with outcome, in contrast to related data from North America.[5](#jah31496-bib-0005){ref-type="ref"}, [37](#jah31496-bib-0037){ref-type="ref"}

Conclusion {#jah31496-sec-0027}
==========

Our findings demonstrate that later unexpected deaths are comparable in scale to early deaths after major intervention for CHD and that, while further improvements in early mortality are possible and important, there may arguably be a diminishing return to improvement initiatives in the perioperative period compared with the postdischarge period because of the relative lack of attention to the latter to date. We note that guidelines for the entire discharge process in "high‐risk infants" (not including CHD) have been proposed by the American Academy of Pediatrics with the aim of reducing variability and maintaining predetermined levels of care,[50](#jah31496-bib-0050){ref-type="ref"} and our study suggests that something similar is warranted for CHD. This would require the development of appropriate intervention packages for patients with different needs, and our findings provide a valuable starting point in designing these. In particular, they show that adverse late outcomes are not confined to diagnostic groups currently targeted with enhanced monitoring in some services (ie, HLHS patients) and that subgroups of patients with neurodevelopmental conditions or congenital anomalies could also benefit from targeted intervention. Finally, to stimulate improvement initiatives aimed at reducing late adverse outcomes and to align activity across organizations responsible for the care of these patients, 1‐year outcome after intervention for CHD in infancy may be a useful quality metric for pediatric cardiac surgery programs to complement the current focus on early mortality rates of surgery at 30 days or hospital discharge.
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